US FDA lifts 18-month clinical hold on MaaT Pharma's microbiome therapeutic

More than a year after imposing a clinical hold on MaaT Pharma’s lead microbiome therapeutic in 2021, the US Food and Drug Administration (FDA) has given clearance for the French firm to begin a phase 3 trial in the US.

Related Keywords

Paris ,France General ,France , ,Maat Pharma ,Investigational New Drug ,Lassistance Publique ,Bio Developments ,Us ,Clinical Trial ,Fda ,